Arcus Biosciences (RCUS) EBIAT: 2017-2025
Historic EBIAT for Arcus Biosciences (RCUS) over the last 7 years, with Sep 2025 value amounting to -$135.0 million.
- Arcus Biosciences' EBIAT fell 46.74% to -$135.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$433.0 million, marking a year-over-year decrease of 60.37%. This contributed to the annual value of -$283.0 million for FY2024, which is 7.82% up from last year.
- As of Q3 2025, Arcus Biosciences' EBIAT stood at -$135.0 million, which was down 20.54% from -$112.0 million recorded in Q1 2025.
- Arcus Biosciences' EBIAT's 5-year high stood at $279.5 million during Q4 2021, with a 5-year trough of -$135.0 million in Q3 2025.
- For the 3-year period, Arcus Biosciences' EBIAT averaged around -$83.7 million, with its median value being -$86.5 million (2023).
- Examining YoY changes over the last 5 years, Arcus Biosciences' EBIAT showed a top increase of 639.10% in 2021 and a maximum decrease of 4,379.64% in 2021.
- Quarterly analysis of 5 years shows Arcus Biosciences' EBIAT stood at $279.5 million in 2021, then plummeted by 123.97% to -$67.0 million in 2022, then dropped by 20.90% to -$81.0 million in 2023, then fell by 16.05% to -$94.0 million in 2024, then slumped by 46.74% to -$135.0 million in 2025.
- Its EBIAT stands at -$135.0 million for Q3 2025, versus -$112.0 million for Q1 2025 and -$94.0 million for Q4 2024.